Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T87024
(Former ID: TTDC00180)
|
|||||
Target Name |
Amyloid beta A4 protein (APP)
|
|||||
Synonyms |
Protease nexin-II; PreA4; PN-II; Cerebral vascular amyloid peptide; CVAP; Amyloid-beta precursor protein; Amyloid-beta A4 protein; Alzheimer disease amyloid protein; APPI; APP; AD1; ABPP; A4
Click to Show/Hide
|
|||||
Gene Name |
APP
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 2 Target-related Diseases | + | ||||
1 | Alzheimer disease [ICD-11: 8A20] | |||||
2 | Diagnostic imaging [ICD-11: N.A.] | |||||
Function |
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.
Click to Show/Hide
|
|||||
BioChemical Class |
Amyloid beta-protein peptide
|
|||||
UniProt ID | ||||||
Sequence |
MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTK
TCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVG EFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFR GVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEE EADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPC RAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARD PVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQA KNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITAL QAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYER MNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTET KTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTN IKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITL VMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
HIT2.0 ID | T01E8J |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 3 Approved Drugs | + | ||||
1 | Aducanumab | Drug Info | Approved | Alzheimer disease | [2] | |
2 | Florbetapir F-18 | Drug Info | Approved | Diagnostic imaging | [3] | |
3 | Lecanemab | Drug Info | Approved | Alzheimer disease | [4] | |
Clinical Trial Drug(s) | [+] 22 Clinical Trial Drugs | + | ||||
1 | ALZT-OP1 | Drug Info | Phase 3 | Alzheimer disease | [9], [10] | |
2 | Bapineuzumab | Drug Info | Phase 3 | Alzheimer disease | [11], [12] | |
3 | Crenezumab | Drug Info | Phase 3 | Alzheimer disease | [9], [10] | |
4 | Curcumin | Drug Info | Phase 3 | Solid tumour/cancer | [13], [14] | |
5 | Gantenerumab | Drug Info | Phase 3 | Alzheimer disease | [15], [16] | |
6 | Solanezumab | Drug Info | Phase 3 | Alzheimer disease | [17], [18] | |
7 | Tramiprosate | Drug Info | Phase 3 | Alzheimer disease | [19] | |
8 | CAD-106 | Drug Info | Phase 2/3 | Alzheimer disease | [20] | |
9 | ALZ-801 | Drug Info | Phase 2 | Alzheimer disease | [9], [10] | |
10 | FRM-0962 | Drug Info | Phase 2 | Alzheimer disease | [26] | |
11 | GSK933776A | Drug Info | Phase 2 | Macular degeneration | [27] | |
12 | Myo-inositol | Drug Info | Phase 2 | Alzheimer disease | [28] | |
13 | Ponezumab | Drug Info | Phase 2 | Alzheimer disease | [29] | |
14 | T-817MA | Drug Info | Phase 2 | Alzheimer disease | [30] | |
15 | UB-311 | Drug Info | Phase 2 | Alzheimer disease | [31] | |
16 | ACI-24 | Drug Info | Phase 1/2 | Alzheimer disease | [32] | |
17 | EB-101 | Drug Info | Phase 1/2 | Dystrophic epidermolysis bullosa | [33] | |
18 | AAB-003/PF-05236812 | Drug Info | Phase 1 | Alzheimer disease | [41] | |
19 | Anti-N3pG-Abeta antibody | Drug Info | Phase 1 | Alzheimer disease | [42] | |
20 | DWP-09031 | Drug Info | Phase 1 | Alzheimer disease | [43] | |
21 | SAR228810 | Drug Info | Phase 1 | Alzheimer disease | [44] | |
22 | Systebryl | Drug Info | Phase 1 | Amyloidosis | [45] | |
Discontinued Drug(s) | [+] 2 Discontinued Drugs | + | ||||
1 | Affitope AD-02 | Drug Info | Discontinued in Phase 2 | Alzheimer disease | [47] | |
2 | PF-05236812 | Drug Info | Discontinued in Phase 1 | Alzheimer disease | [48] | |
Preclinical Drug(s) | [+] 3 Preclinical Drugs | + | ||||
1 | AAB-002 | Drug Info | Phase 0 | Alzheimer disease | [49] | |
2 | NN-818 | Drug Info | Preclinical | Brain injury | [50] | |
3 | Pepticlere | Drug Info | Preclinical | Alzheimer disease | [51] | |
Mode of Action | [+] 4 Modes of Action | + | ||||
Modulator | [+] 17 Modulator drugs | + | ||||
1 | Aducanumab | Drug Info | [52] | |||
2 | Florbetapir F-18 | Drug Info | [1] | |||
3 | Lecanemab | Drug Info | [53] | |||
4 | Crenezumab | Drug Info | [55] | |||
5 | Solanezumab | Drug Info | [57] | |||
6 | FRM-0962 | Drug Info | [61] | |||
7 | GSK933776A | Drug Info | [62] | |||
8 | UB-311 | Drug Info | [64] | |||
9 | AAB-003/PF-05236812 | Drug Info | [55] | |||
10 | AAB-002 | Drug Info | [55] | |||
11 | NN-818 | Drug Info | [55] | |||
12 | 123I-DRM-106 | Drug Info | [55] | |||
13 | 18F-AV-45 dimer | Drug Info | [55] | |||
14 | BAN-2203 | Drug Info | [55] | |||
15 | EDN-OL1 | Drug Info | [55] | |||
16 | Gamma-secretase modulators | Drug Info | [55] | |||
17 | TKP-1001 | Drug Info | [55] | |||
Inhibitor | [+] 53 Inhibitor drugs | + | ||||
1 | ALZT-OP1 | Drug Info | [10] | |||
2 | Curcumin | Drug Info | [56] | |||
3 | ALZ-801 | Drug Info | [60] | |||
4 | Myo-inositol | Drug Info | [28] | |||
5 | T-817MA | Drug Info | [9], [10] | |||
6 | DWP-09031 | Drug Info | [55] | |||
7 | Systebryl | Drug Info | [55] | |||
8 | PF-05236812 | Drug Info | [52] | |||
9 | Pepticlere | Drug Info | [69] | |||
10 | 1,6-bis(4'-dimethylaminophenyl)-hexa-1,3,5-triene | Drug Info | [70] | |||
11 | 1,6-Bis(4'-hydroxyphenyl)-hexa-1,3,5-triene | Drug Info | [70] | |||
12 | 1,6-bis(4'-nitrophenyl)-hexa-1,3,5-triene | Drug Info | [70] | |||
13 | 2,5-bis(2-methoxyphenyl)thiophene | Drug Info | [71] | |||
14 | 2,5-bis(4-Hydroxyphenyl)thiophene | Drug Info | [71] | |||
15 | 2,5-bis(4-methoxyphenyl)thiophene | Drug Info | [71] | |||
16 | 2,5-bis(4-nitrophenyl)thiophene | Drug Info | [71] | |||
17 | 2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol | Drug Info | [70] | |||
18 | 2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene | Drug Info | [71] | |||
19 | 4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol | Drug Info | [71] | |||
20 | 4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine | Drug Info | [71] | |||
21 | 4-(5-(4-aminophenyl)thiophen-2-yl)phenol | Drug Info | [71] | |||
22 | 4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine | Drug Info | [71] | |||
23 | 4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol | Drug Info | [71] | |||
24 | 5-hydroxy-2-(4-aminophenyl)benzofuran | Drug Info | [72] | |||
25 | 5-hydroxy-2-(4-dimethylaminophenyl)benzofuran | Drug Info | [72] | |||
26 | 5-hydroxy-2-(4-methylaminophenyl)benzofuran | Drug Info | [72] | |||
27 | 5-methoxy-2-(4-aminophenyl)benzofuran | Drug Info | [72] | |||
28 | 5-methoxy-2-(4-dimethylaminophenyl)benzofuran | Drug Info | [72] | |||
29 | 5-methoxy-2-(4-methylaminophenyl)benzofuran | Drug Info | [72] | |||
30 | 6-iodo-4'-dimethyaminoflavone | Drug Info | [73] | |||
31 | 6-iodo-4'-methoxyflavone | Drug Info | [73] | |||
32 | 6-iodo-4'-methylaminoflavone | Drug Info | [73] | |||
33 | A-887755 | Drug Info | [55] | |||
34 | Abloid | Drug Info | [55] | |||
35 | ACI-636 | Drug Info | [55] | |||
36 | ANA-5 | Drug Info | [55] | |||
37 | Anticalin | Drug Info | [55] | |||
38 | ARC-069 | Drug Info | [55] | |||
39 | ARN-2966 | Drug Info | [55] | |||
40 | AZ4800 | Drug Info | [74] | |||
41 | Chrysamine -G | Drug Info | [56] | |||
42 | CT-003230 | Drug Info | [55] | |||
43 | DBT-1339 | Drug Info | [55] | |||
44 | DEHYDROZINGERONE | Drug Info | [56] | |||
45 | ELND-007 | Drug Info | [75] | |||
46 | KMS-88009 | Drug Info | [55] | |||
47 | SB-13 | Drug Info | [70] | |||
48 | SEM-606 | Drug Info | [55] | |||
49 | SEN-1500 | Drug Info | [55] | |||
50 | SP-08 | Drug Info | [55] | |||
51 | SR-973 | Drug Info | [77] | |||
52 | Turmeric extracts | Drug Info | [55] | |||
53 | VK-12 | Drug Info | [55] | |||
Antagonist | [+] 1 Antagonist drugs | + | ||||
1 | Tramiprosate | Drug Info | [58] | |||
Agonist | [+] 1 Agonist drugs | + | ||||
1 | CD45RB | Drug Info | [55] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: Phosphonate | Ligand Info | |||||
Structure Description | S8 phosphorylated beta amyloid 40 fibrils | PDB:6OC9 | ||||
Method | Solid-state NMR | Resolution | N.A. | Mutation | No | [78] |
PDB Sequence |
DAEFRHDSGY
10 EVHHQKLVFF20 AEDVGSNKGA30 IIGLMVGGVV40
|
|||||
|
||||||
Ligand Name: (R)-butane-1,3-diol | Ligand Info | |||||
Structure Description | Structure of the Heparin-induced E1-Dimer of the Amyloid Precursor Protein (APP) | PDB:3KTM | ||||
Method | X-ray diffraction | Resolution | 2.70 Å | Mutation | No | [79] |
PDB Sequence |
LLAEPQIAMF
37 CGRLNMHMNV47 QNGKWDSDPS57 GTKTCIDTKE67 GILQYCQEVY77 PELQITNVVE 87 ANQPVTIQNW97 CKRGRKQCKT107 HPHFVIPYRC117 LVGEFVSDAL127 LVPDKCKFLH 137 QERMDVCETH147 LHWHTVAKET157 CSEKSTNLHD167 YGMLLPCGID177 KFRGVEFVCC 187 PLAIEGRKLA197 AALEH
|
|||||
|
||||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Serotonergic synapse | hsa04726 | Affiliated Target |
|
Class: Organismal Systems => Nervous system | Pathway Hierarchy |
Degree | 46 | Degree centrality | 4.94E-03 | Betweenness centrality | 9.37E-03 |
---|---|---|---|---|---|
Closeness centrality | 2.57E-01 | Radiality | 1.45E+01 | Clustering coefficient | 4.35E-02 |
Neighborhood connectivity | 2.19E+01 | Topological coefficient | 3.14E-02 | Eccentricity | 11 |
Download | Click to Download the Full PPI Network of This Target | ||||
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 2 KEGG Pathways | + | ||||
1 | Notch signaling pathway | |||||
2 | Alzheimer's disease | |||||
Reactome | [+] 8 Reactome Pathways | + | ||||
1 | Nuclear signaling by ERBB4 | |||||
2 | Degradation of the extracellular matrix | |||||
3 | Regulated proteolysis of p75NTR | |||||
4 | NRIF signals cell death from the nucleus | |||||
5 | Activated NOTCH1 Transmits Signal to the Nucleus | |||||
6 | Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||||
7 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||||
8 | EPH-ephrin mediated repulsion of cells | |||||
WikiPathways | [+] 9 WikiPathways | + | ||||
1 | Notch Signaling Pathway | |||||
2 | Signaling by ERBB4 | |||||
3 | Signaling by NOTCH3 | |||||
4 | Signaling by NOTCH4 | |||||
5 | Signaling by NOTCH1 | |||||
6 | Signaling by NOTCH2 | |||||
7 | Notch Signaling Pathway | |||||
8 | Alzheimers Disease | |||||
9 | Signalling by NGF |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 2 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761178. | |||||
REF 3 | Nat Rev Drug Discov. 2013 Feb;12(2):87-90. | |||||
REF 4 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761269. | |||||
REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8325). | |||||
REF 6 | ClinicalTrials.gov (NCT02484547) 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease. | |||||
REF 7 | ClinicalTrials.gov (NCT02293915) Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer Disease. U.S.National Institutes of Health. | |||||
REF 8 | ClinicalTrials.gov (NCT05108922) A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease. U.S.National Institutes of Health. | |||||
REF 9 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 10 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 11 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6930). | |||||
REF 12 | Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):322-33. | |||||
REF 13 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7000). | |||||
REF 14 | Nanocurcumin: a promising therapeutic advancement over native curcumin. Crit Rev Ther Drug Carrier Syst. 2013;30(4):331-68. | |||||
REF 15 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6933). | |||||
REF 16 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015121) | |||||
REF 17 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6932). | |||||
REF 18 | ClinicalTrials.gov (NCT01900665) Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo. U.S. National Institutes of Health. | |||||
REF 19 | ClinicalTrials.gov (NCT00314912) Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 20 | ClinicalTrials.gov (NCT02565511) A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease. | |||||
REF 21 | ClinicalTrials.gov (NCT00021723) Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 22 | ClinicalTrials.gov (NCT01928420) A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 23 | ClinicalTrials.gov (NCT03790982) A Randomized, Double Blind, Placebo Controlled, Parallel-Group 52-week Multicenter Phase II Study to Investigate the Safety, Efficacy and Pharmacokinetics of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease. U.S.National Institutes of Health. | |||||
REF 24 | ClinicalTrials.gov (NCT05291234) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects With Early Alzheimer's Disease. U.S.National Institutes of Health. | |||||
REF 25 | Clinical pipeline report, company report or official report of Roche | |||||
REF 26 | Clinical pipeline report, company report or official report of Forum pharmaceuticals. | |||||
REF 27 | ClinicalTrials.gov (NCT01342926) Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration. U.S. National Institutes of Health. | |||||
REF 28 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 29 | ClinicalTrials.gov (NCT01821118) Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy. U.S. National Institutes of Health. | |||||
REF 30 | ClinicalTrials.gov (NCT02079909) Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202). U.S. National Institutes of Health. | |||||
REF 31 | ClinicalTrials.gov (NCT02551809) Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients. | |||||
REF 32 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031074) | |||||
REF 33 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 34 | ClinicalTrials.gov (NCT00838877) Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for A Amyloid. U.S. National Institutes of Health. | |||||
REF 35 | ClinicalTrials.gov (NCT00495417) Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 36 | List of drugs in development for neurodegenerative diseases: update October 2011. Neurodegener Dis. 2012;9(4):210-83. | |||||
REF 37 | ClinicalTrials.gov (NCT04931459) A Phase 1 Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous ACU193 in Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease. U.S.National Institutes of Health. | |||||
REF 38 | ClinicalTrials.gov (NCT04476303) A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of BEY2153 After Oral Administration in Healthy Young and Elderly Male Volunteers. U.S.National Institutes of Health. | |||||
REF 39 | Clinical pipeline report, company report or official report of Annovis Bio | |||||
REF 40 | ClinicalTrials.gov (NCT04451408) A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants. U.S.National Institutes of Health. | |||||
REF 41 | ClinicalTrials.gov (NCT01369225) Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 42 | ClinicalTrials.gov (NCT01837641) A Study of LY3002813 in Participants With Alzheimer's Disease. U.S. National Institutes of Health. | |||||
REF 43 | ClinicalTrials.gov (NCT01522586) Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031. U.S. National Institutes of Health. | |||||
REF 44 | ClinicalTrials.gov (NCT01485302) Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients. U.S. National Institutes of Health. | |||||
REF 45 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 46 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031573) | |||||
REF 47 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029150) | |||||
REF 48 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030748) | |||||
REF 49 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024936) | |||||
REF 50 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020811) | |||||
REF 51 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023984) | |||||
REF 52 | Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18. | |||||
REF 53 | The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88. | |||||
REF 54 | Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82. | |||||
REF 55 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). | |||||
REF 56 | Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9. | |||||
REF 57 | Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21. | |||||
REF 58 | Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47. | |||||
REF 59 | The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011 Jun 22;31(25):9323-31. | |||||
REF 60 | Oral Clinical Candidate ALZ-801 in Alzheon's pipeline. 2012. | |||||
REF 61 | Gamma-secretase. SciBX 7(40); doi:10.1038/scibx.2014.1175. Oct. 16 2014 | |||||
REF 62 | Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Correction in: Drug Des Devel Ther. 2014; 8: 569. | |||||
REF 63 | Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012 Aug 24;421(4-5):525-36. | |||||
REF 64 | Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther. 2014; 6(1): 7. | |||||
REF 65 | Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener. 2013; 8: 36. | |||||
REF 66 | LY3002813 Alzheimer's Disease (Phase 1). Eli Lilly & Co. | |||||
REF 67 | SAR228810: An antiprotofibrillar beta-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA). Alzheimer's & Dementia Volume 9, Issue 4, Supplement, July 2013, Pages P808-P809. | |||||
REF 68 | Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol. 2014 Mar;10(3):405-19. | |||||
REF 69 | Preclinical trail of Pepticlere (DP-74) for treating Alzheimer's disease. ProteoTech Inc. | |||||
REF 70 | Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4. | |||||
REF 71 | Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2. | |||||
REF 72 | Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30. | |||||
REF 73 | Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem. 2005 Nov 17;48(23):7253-60. | |||||
REF 74 | First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms. J Biol Chem. 2012 Apr 6;287(15):11810-9. | |||||
REF 75 | Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease Volume 82, October 2015, Pages 385-396. | |||||
REF 76 | Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci. 2003 Jan 1;23(1):29-33. | |||||
REF 77 | Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. | |||||
REF 78 | Molecular structure of an N-terminal phosphorylated beta-amyloid fibril. Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11253-11258. | |||||
REF 79 | Structure and biochemical analysis of the heparin-induced E1 dimer of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5381-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.